Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Foghorn Therapeutics Inc

FHTX
Current price
8.3 USD +0.43 USD (+5.46%)
Last closed 7.62 USD
ISIN US3441741077
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 427 137 568 USD
Yield for 12 month +116.71 %
1Y
3Y
5Y
10Y
15Y
FHTX
21.11.2021 - 28.11.2021

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 500 Technology Square, Cambridge, MA, United States, 02139

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

16 USD

P/E ratio

Dividend Yield

Current Year

+34 155 000 USD

Last Year

+19 228 000 USD

Current Quarter

+6 888 000 USD

Last Quarter

+5 050 000 USD

Current Year

+25 494 000 USD

Last Year

+19 208 772 USD

Current Quarter

+6 088 000 USD

Last Quarter

+4 215 000 USD

Key Figures FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -91 625 000 USD
Operating Margin TTM -351.83 %
PE Ratio
Return On Assets TTM -17.77 %
PEG Ratio
Return On Equity TTM -470.38 %
Wall Street Target Price 16 USD
Revenue TTM 35 185 000 USD
Book Value -0.26 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 23 %
Dividend Yield
Gross Profit TTM -86 390 000 USD
Earnings per share -1.93 USD
Diluted Eps TTM -1.93 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -245.69 %

Dividend Analytics FHTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FHTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 5.1976
Price Sales TTM 12.1398
Enterprise Value EBITDA -1.2144
Price Book MRQ 10.707

Financials FHTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FHTX

For 52 weeks

2.7 USD 10.25 USD
50 Day MA 8.27 USD
Shares Short Prior Month 1 195 340
200 Day MA 6.41 USD
Short Ratio 6.83
Shares Short 1 326 842
Short Percent 3.18 %